JP Morgan Chase
EWTX icon

JP Morgan Chase’s Edgewise Therapeutics EWTX Stock Holding History

JP Morgan Chase’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,100
Closed -$904K – 7243
2025
Q1 		$904K Buy
+41,100
New +$1.08M ﹤0.01% 4421

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase's EWTX Position: Q1 2026 in Review

JP Morgan Chase increased its Edgewise Therapeutics (EWTX) stake by 1.1% in Q1 2026, buying an estimated $44.3K and bringing the position to 147,573 shares worth $4.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3423.

JP Morgan Chase first reported a position in EWTX in Q2 2021 and has held it in 20 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • JP Morgan Chase held 147,573 shares of Edgewise Therapeutics worth $4.47M as of Q1 2026.
  • JP Morgan Chase bought 1,535 Edgewise Therapeutics shares in Q1 2026, an estimated $44.3K.
  • Edgewise Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3423 holding.
  • JP Morgan Chase first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.